Navigation Links
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
Date:6/13/2008

acy end points, like the Modified Osteoarthritis Research Society International (OARSI) responder rate, a visual analog scale (VAS) of pain intensity during rest or walking and investigators' overall rating of disease status, treatment and response to therapy, also showed positive results.

Study design: 301 was a 13-week, double-blind, placebo and naproxen- controlled trial, in patients with osteoarthritis of the knee. 918 eligible patients were randomized on a 1:1:1:1 basis at 120 clinical sites in the United States to receive: naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 500 mg bid or placebo bid. Eligible patients were at least 40 years old, with a clinical diagnosis of primary osteoarthritis of the knee of at least 3 months duration, confirmed by radiographs, and diagnosed according to the ACR guidelines (patients must have qualified as ACR global functional status I, II or III). There were no statistically significant differences among the four treatment groups for any baseline variables, including hypertension medical history (approximately half of enrolled patients had a medical history of hypertension at baseline).

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
2. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
3. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
4. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
7. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
8. NicOx Naproxcinod ABPM Data Presented at American Heart Association
9. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
10. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
11. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)...  Eli Lilly and Company (NYSE: LLY ) ... of its intent to end its contract with the ... Asymptomatic Alzheimer,s disease (A4) study. The A4 study is ... stage of Alzheimer,s disease in older individuals who have ... scan, but do not show symptoms of memory impairment. ...
(Date:8/4/2015)... 4, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... Ch.B., Sangamo,s executive vice president, research and development, will ... Therapeutic ® development programs and an overview of ... August 11, 2015, at the 2015 Wedbush Pacgrow Healthcare ... New York, NY . The presentation ...
(Date:8/4/2015)... Calif., Aug. 4, 2015  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... reported financial results for the second quarter ended June ... business highlights. "Currently eight XmAb® antibody ... and two internal. The accelerating momentum of this ...
Breaking Medicine Technology:Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study 2Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study 3Sangamo BioSciences Announces Presentation At The 2015 Wedbush Pacgrow Healthcare Conference 2Xencor Reports Second Quarter 2015 Financial and Operating Results 2Xencor Reports Second Quarter 2015 Financial and Operating Results 3Xencor Reports Second Quarter 2015 Financial and Operating Results 4Xencor Reports Second Quarter 2015 Financial and Operating Results 5Xencor Reports Second Quarter 2015 Financial and Operating Results 6Xencor Reports Second Quarter 2015 Financial and Operating Results 7Xencor Reports Second Quarter 2015 Financial and Operating Results 8Xencor Reports Second Quarter 2015 Financial and Operating Results 9
... ago, Keli Babcock faced a crisis. A medical condition was ... a ventilator. She couldn,t walk or even maneuver a manual ... But Keli wasn,t about to give in; she aspired to ... with a power wheelchair, one that is powered by batteries ...
... Innovative wireless technology is reshaping the healthcare landscape in ... of Wireless" webcast ( www.ctia.org ) focuses on new ... more value and better health. This is particularly true ... of the U.S. population suffers from at least one ...
Cached Medicine Technology:Mobility Matters: Power Wheelchairs Change the Lives of Medicare Beneficiaries 2Mobility Matters: Power Wheelchairs Change the Lives of Medicare Beneficiaries 3Mobility Matters: Power Wheelchairs Change the Lives of Medicare Beneficiaries 4CTIA-The Wireless Association® November Edition of 'Wonder of Wireless' and Blog to Focus on mHealth 2CTIA-The Wireless Association® November Edition of 'Wonder of Wireless' and Blog to Focus on mHealth 3
(Date:8/4/2015)... ... 05, 2015 , ... Renowned review site BestMillionaireDatingSites.com recently refreshed its list of ... been ranked as the best dating service in the segment. , A representative from ... is essential that people find the right dating platform so that they can make ...
(Date:8/4/2015)... ... August 04, 2015 , ... NOVA Pride , Northern ... or how they love or identify, to join them in paving “The Road Ahead” ... Special Events Center on Saturday, October 3, 2015, from 12-9pm. In order to ensure ...
(Date:8/4/2015)... ... , ... Statement by Paul Gionfriddo, President and CEO, Mental Health America , ... Act of 2015 by Senators Bill Cassidy and Christopher Murphy. It is ... , “This legislation and H.R. 2646 [The Helping Families in Mental Health ...
(Date:8/4/2015)... ... August 04, 2015 , ... Sponsored by Gila River ... which is a 501(c) nonprofit organization. , According to the New Foundation AZ ... will get a package that includes a complimentary foursome for the tournament, as well ...
(Date:8/4/2015)... ... August 04, 2015 , ... Exsurco Medical, Inc. ... Tissue Banks (AATB) as an Affiliate Member. Exsurco Medical finds this an ... save and improve lives by promoting the safety, quality and availability of donated ...
Breaking Medicine News(10 mins):Health News:BestMillionaireDatingSites.com Publishes Reviews of the Best Dating Sites for Wealthy Singles 2Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 2Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 3Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 4Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 3Health News:The New Foundation AZ to Host Charity Golf Tournament 2Health News:The New Foundation AZ to Host Charity Golf Tournament 3Health News:Exsurco Medical Joins AATB as Affiliate Member 2
... a new definition to identify children and adolescents ... diabetes and cardiovascular disease in later life. The ... ,The metabolic syndrome is a cluster of the most ... disease. Its early identification is very important to facilitate ...
... Rachel Hunter became quite worried about her weight after a ... ,The former wife of rocker Rod Stewart is the ... that she was really concerned about her weight when the ... what's wrong with me? Do I look fat," Contactmusic quoted ...
... annual HealthGrades Womens Health Outcomes in U.S. Hospitals ... nation's best- performing hospitals have a 39 percent ... women at the nation's poorest-performing hospitals. ... largest quality gaps between the best-performing and poorest-performing ...
... reportedly planning to undergo a foot surgery . ... because of her painful bunions and has decided to get ... enough of having bad feet and has made some early-stage ... Mail quoted the source, as saying. ,"They are ...
... Mumbai, June 25 (IANS) Indian pharmaceutical major Ranbaxy Laboratories ... pravastatin sodium tablets, meant for heart diseases . ... 180-day exclusivity for the pravastatin 80mg and benefit from ... Bombay Stock Exchange (BSE). ,The annual sales ...
... is more effective than one-on-one phone counseling. As Americans ... provide feedback and motivation can play a crucial role ... ,Researchers found feedback delivered via mail was equally ... and potentially more effective long-term than feedback delivered via ...
Cached Medicine News:Health News:New Definition Helps Identify Children at Risk of Metabolic Syndrome 2Health News:Best-performing Hospitals Has Reduced Cardiovascular Mortality 2Health News:Physical Activity can Be Increased by a Motivating Mail 2Health News:Physical Activity can Be Increased by a Motivating Mail 3
... The Tomey Pachymeter SP-3000 covers all ... the general ophthalmic health care., ,Compact design, ... the SP-3000 to be an "easy-to-use unit.,The ... 1500 mm gives you the possibility to ...
The PillCam™ ESO video capsule is specifically designed to view the inner lining of the Esophagus. The capsule is equipped with miniature cameras on both ends and is about the size of a multi-v...
... combines three advanced technologies - plus ... refractive diagnostic workstation. Now, with a ... corneal topography, optical path difference (OPD) ... allows you to evaluate your patient ...
World's first commercially available vacuum assisted biopsy device for MRI....
Medicine Products: